Zur Seitenansicht
 

Titelaufnahme

Titel
Advances in recombinant antibody manufacturing
VerfasserKunert, Renate ; Reinhart, David
Erschienen in
Applied Microbiology and Biotechnology, Berlin, 2016, Jg. 100, H. 8, S. 3451-3461
ErschienenSpringer, 2016
SpracheEnglisch
DokumenttypAufsatz in einer Zeitschrift
Schlagwörter (EN)Chinese hamster ovary (CHO) / Human embryonic kidney (HEK) / NSo / PER.C6 / Monoclonal antibody (mAb)manufacturing / Mammalian expression systems / Process advances / Optimization strategies
ISSN1432-0614
URNurn:nbn:at:at-ubbw:3-1437 Persistent Identifier (URN)
DOI10.1007/s00253-016-7388-9 
Zugriffsbeschränkung
 Das Werk ist frei verfügbar
Dateien
Advances in recombinant antibody manufacturing [0.41 mb]
Links
Nachweis
Klassifikation
Zusammenfassung (Englisch)

Since the first use of Chinese hamster ovary (CHO) cells for recombinant protein expression, production processes have steadily improved through numerous advances. In this review, we have highlighted several key milestones that have contributed to the success of CHO cells from the beginning of their use for monoclonal antibody (mAb) expression until today. The main factors influencing the yield of a production process are the time to accumulate a desired amount of biomass, the process duration, and the specific productivity. By comparing maximum cell densities and specific growth rates of various expression systems, we have emphasized the limiting parameters of different cellular systems and comprehensively described scientific approaches and techniques to improve host cell lines. Besides the quantitative evaluation of current systems, the quality-determining properties of a host cell line, namely post-translational modifications, were analyzed and compared to naturally occurring polyclonal immunoglobulin fractions from human plasma. In summary, numerous different expression systems for mAbs are available and also under scientific investigation. However, CHO cells are the most frequently investigated cell lines and remain the workhorse for mAb production until today.